Management of diastolic heart failure

International Conference on World Heart Care

November 07-08, 2022 | Webinar

Keyur Mavani

Dr. at Geisinger clinic and Geisinger Commonwealth School of Medicine, USA

Scientific Tracks Abstracts: J Interv Gen Cardiol

Abstract :

According to research so far, there are more than 50 % of heart failure admissions are due to heart failure with preserved ejection fraction. Given patient related factors such as lung illnesses or weight, sometimes it becomes challenging to diagnose heart failure with preserved ejection fraction. There are ways to look for diastolic heart failure (heart failure with preserved ejection fraction HEpEF, heart failure with mid-range ejectgion fraction HemEF or heart failure with recovered ejection fraction HervEF) as it is important for treating patient appropriately and reduce heart failure admissions and readmissions leading to increased health care expenditure. I will be talking about how to diagnose it with various tests such as echocardiography, examination, history and sometimes invasive cardiac catheterization especially right heart catheterization. We do not have proper and specific treatment options for diastolic CHF so far. However, there has been lot of advances made in this area of cardiology. I will discuss trials and medications approved to treat diastolic CHF along with pathophysiology related treatment options. We will shortly discuss treatment options for amyloidosis and hypertrophic cardiomyopathy as there are more advances in these area recently.

Biography :

Dr. Keyur Mavani has completed cardiovascular disease fellowship at age of 35 and working as a consultant cardiologist. He also teaches medical students, internal medicine and family medicine residents along with cardiology fellows in training. He has published some articles and presented abstracts in various conferences. He is a Clinical Assistant Professor of Medicine for about 12 years at Scranton PA and did serve in same role for Virginia Commonwealth University Richmond Virginia USA for 2 years.